Short Interest in Indivior PLC (NASDAQ:INDV) Increases By 552.0%

Indivior PLC (NASDAQ:INDV) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 950,000 shares, a growth of 552.0% from the August 31st total of 145,700 shares. Based on an average trading volume of 815,500 shares, the short-interest ratio is currently 1.2 days. Approximately 0.7% of the shares of the stock are short sold.

Institutional Investors Weigh In On Indivior

Several institutional investors have recently bought and sold shares of INDV. Bank of New York Mellon Corp acquired a new position in shares of Indivior during the 2nd quarter worth approximately $188,000. VELA Investment Management LLC acquired a new position in Indivior during the second quarter worth $235,000. XTX Topco Ltd acquired a new stake in shares of Indivior in the second quarter valued at $249,000. Chilton Investment Co. Inc. acquired a new stake in shares of Indivior in the fourth quarter valued at $263,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Indivior in the fourth quarter valued at $368,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Price Performance

INDV stock traded up $0.11 during trading on Wednesday, hitting $9.43. The stock had a trading volume of 202,940 shares, compared to its average volume of 357,493. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. Indivior has a twelve month low of $9.05 and a twelve month high of $23.22. The stock has a market capitalization of $1.30 billion, a P/E ratio of 930.00 and a beta of 0.68. The company’s 50-day moving average price is $11.65 and its two-hundred day moving average price is $15.66.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.04. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. The company had revenue of $299.00 million for the quarter, compared to analysts’ expectations of $285.90 million. As a group, research analysts predict that Indivior will post 1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Craig Hallum dropped their target price on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. Piper Sandler restated an “overweight” rating and set a $22.00 target price on shares of Indivior in a research report on Friday, September 13th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.